Nazia Chaudhuri

List of Publications by Citations

61 papers	1,316 citations	19 h-index	35 g-index
99 ext. papers	1,924 ext. citations	7 avg, IF	4.71 L-index

#	Paper	IF	Citations
61	Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. *Lancet Respiratory Medicine,the*, **2020**, 8, 453-460	35.1	154
60	Drug-Induced Interstitial Lung Disease: A Systematic Review. *Journal of Clinical Medicine*, **2018**, 7,	5.1	117
59	Idiopathic Pulmonary Fibrosis (IPF): An Overview. *Journal of Clinical Medicine*, **2018**, 7,	5.1	111
58	Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis. *Journal of Clinical Medicine*, **2016**, 5,	5.1	102
57	Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 202, 1656-1665	10.2	72
56	The therapy of idiopathic pulmonary fibrosis: what is next?. *European Respiratory Review*, **2019**, 28,	9.8	68
55	Association of Cardiovascular Disease With Respiratory Disease. *Journal of the American College of Cardiology*, **2019**, 73, 2166-2177	15.1	60
54	Toll-like receptors and chronic lung disease. *Clinical Science*, **2005**, 109, 125-33	6.5	59
53	Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis. *Respiratory Medicine*, **2014**, 108, 224-6	4.6	52
52	Reducing the toll of inflammatory lung disease. *Chest*, **2007**, 131, 1550-6	5.3	39
51	Persistent self-reported changes in hearing and tinnitus in post-hospitalisation COVID-19 cases. *International Journal of Audiology*, **2020**, 59, 889-890	2.6	38
50	Summary of the British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults. *Thorax*, **2013**, 68, 786-7	7.3	37
49	Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. *Lancet Respiratory Medicine,the*, **2019**, 7, 771-779	35.1	34
48	IPF Care: a support program for patients with idiopathic pulmonary fibrosis treated with pirfenidone in Europe. *Advances in Therapy*, **2015**, 32, 87-107	4.1	28
47	Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse Events. *Respiration*, **2019**, 97, 173-184	3.7	27
46	Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience. *Therapeutic Advances in Respiratory Disease*, **2018**, 12, 1753466618800618	4.9	27
45	A Review of the Multidisciplinary Diagnosis of Interstitial Lung Diseases: A Retrospective Analysis in a Single UK Specialist Centre. *Journal of Clinical Medicine*, **2016**, 5,	5.1	26

44	Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres. *Clinical and Translational Medicine*, **2017**, 6, 41	5.7	23
43	Basic science of the innate immune system and the lung. *Paediatric Respiratory Reviews*, **2008**, 9, 236-42	4.8	22
42	Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. *European Respiratory Journal*, **2020**, 55,	13.6	18
41	Diesel exhaust particle exposure in vitro alters monocyte differentiation and function. *PLoS ONE*, **2012**, 7, e51107	3.7	18
40	Idiopathic pulmonary fibrosis: a holistic approach to disease management in the antifibrotic age. *Journal of Thoracic Disease*, **2017**, 9, 4700-4707	2.6	17
39	Bagpipe lung; a new type of interstitial lung disease?. *Thorax*, **2017**, 72, 380-382	7.3	14
38	Sarcoidosis in the UK: insights from British Thoracic Society registry data. *BMJ Open Respiratory Research*, **2019**, 6, e000357	5.6	13
37	Breath biomarkers in idiopathic pulmonary fibrosis: a systematic review. *Respiratory Research*, **2019**, 20, 7	7.3	13
36	Substrate for the Myocardial Inflammation-Heart Failure Hypothesis Identified Using Novel USPIO Methodology. *JACC: Cardiovascular Imaging*, **2021**, 14, 365-376	8.4	13
35	No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone. *European Respiratory Journal*, **2019**, 53,	13.6	12
34	Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?. *Drugs and Aging*, **2017**, 34, 647-653	4.7	9
33	Treatment of fibrotic interstitial lung disease: current approaches and future directions. *Lancet, The* , **2021**, 398, 1450-1460	40	7
32	Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID). *BMJ Open Respiratory Research*, **2021**, 8,	5.6	6
31	Drug induced interstitial lung disease: a systematic review **2018**,		5
30	Idiopathic pulmonary fibrosis in the UK: analysis of the British Thoracic Society electronic registry between 2013 and 2019. *ERJ Open Research*, **2021**, 7,	3.5	5
29	The burden of progressive fibrotic interstitial lung disease across the UK. *European Respiratory Journal*, **2021**, 58,	13.6	5
28	Myocardial involvement in eosinophilic granulomatosis with polyangiitis evaluated with cardiopulmonary magnetic resonance. *International Journal of Cardiovascular Imaging*, **2021**, 37, 1371-1381	2.5	5
27	Conventional oxygen therapy versus CPAP as a ceiling of care in ward-based patients with COVID-19: a multi-centre cohort evaluation. *EClinicalMedicine*, **2021**, 40, 101122	11.3	5

26	Physiological predictors of Hypoxic Challenge Testing (HCT) outcomes in Interstitial Lung Disease (ILD). *Respiratory Medicine*, **2018**, 135, 51-56	4.6	4
25	Transbronchial Lung Cryobiopsy in Idiopathic Pulmonary Fibrosis: A State of the Art Review. *Advances in Therapy*, **2019**, 36, 2193-2204	4.1	4
24	S91 A randomised, double-blind, placebo-controlled crossover study to assess the efficacy of a single dose of 100 mg of VRP700 by inhalation in reducing the frequency and severity of cough in adult patients with Idiopathic Pulmonary Fibrosis. *Thorax*, **2015**, 70, A52.1-A52	7.3	4
23	A global perspective on acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF): results from an international survey **2018**,		4
22	How consistently do physicians diagnose and manage drug-induced interstitial lung disease? Two surveys of European ILD specialist physicians. *ERJ Open Research*, **2020**, 6,	3.5	4
21	Feather bedding as a cause of hypersensitivity pneumonitis. *QJM - Monthly Journal of the Association of Physicians*, **2017**, 110, 233-234	2.7	3
20	P28 Real World MDT Diagnosis of Idiopathic Pulmonary Fibrosis. *Thorax*, **2015**, 70, A90.1-A90	7.3	3
19	Outcome of hospitalisation for COVID-19 in patients with Interstitial Lung Disease: An international multicentre study.		3
18	Pulmonary Sequelae at 4 Months After COVID-19 Infection: A Single-Centre Experience of a COVID Follow-Up Service. *Advances in Therapy*, **2021**, 38, 4505-4519	4.1	3
17	Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World. *Frontiers in Medicine*, **2021**, 8, 699644	4.9	3
16	Current Treatments in the Management of Idiopathic Pulmonary Fibrosis: Pirfenidone and Nintedanib. *Clinical Medicine Insights Therapeutics*, **2017**, 9, 1179559X1771912	0	2
15	Real world experience of response to pirfenidone in patients with idiopathic pulmonary fibrosis: a two centre retrospective study. *Sarcoidosis Vasculitis and Diffuse Lung Diseases*, **2020**, 37, 218-224	1.1	2
14	Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment. *Advances in Therapy*, **2021**, 38, 268-277	4.1	2
13	Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial. *European Respiratory Journal*, **2021**, 58,	13.6	2
12	The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease. *Expert Review of Respiratory Medicine*, **2020**, 14, 1001-1008	3.8	1
11	Rapidly non-ipf progressive fibrosing interstitial lung disease: a phenotype with an ipf-like behavior. *Sarcoidosis Vasculitis and Diffuse Lung Diseases*, **2020**, 37, 231-233	1.1	1
10	Nintedanib for treating idiopathic pulmonary fibrosis. *British Journal of Health Care Management*, **2016**, 22, 250-251	0.4	
9	Idiopathic pulmonary fibrosis: a clinical update. *British Journal of General Practice*, **2018**, 68, 249-250	1.6	

List of Publications

8	P280 Extended Clinical Experience With Pirfenidone During A Named Patient Programme For Idiopathic Pulmonary Fibrosis (ipf): Interim Results. *Thorax*, **2014**, 69, A196-A196	7.3
7	M263 A Quarter Of Ipf Patients Not Eligible For Pirfenidone Treatment Due To The Nice Criteria Significantly Decline Over Time. *Thorax*, **2014**, 69, A218-A218	7.3
6	M264 Health And Economic Impact Of Prescribing Pirfenidone. *Thorax*, **2014**, 69, A218-A219	7.3
5	P6 Early Clinical Experience With Nintedanib two centre review. *Thorax*, **2015**, 70, A77.2-A77	7.3
4	P34 Sarcoidosis and co-existent Aspergillus lung disease. *Thorax*, **2015**, 70, A92.3-A93	7.3
3	S13 Sole use of forced vital capacity as per national institute of health and care excellence criteria disadvantage 2 in 5 people with idiopathic pulmonary fibrosis. *Thorax*, **2013**, 68, A10.1-A10	7.3
2	Pulmonary involvement in antiphospholipid syndrome **2019**, 124-139	
1	Reply to Althuwaybi : Hospitalization Outcomes for COVID-19 in Patients with Interstitial Lung Disease: A Potential Role for Aerodigestive Pathophysiology?. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 522-524	10.2